Human astrocytoma CCF1 cells were cultured in RPMI medium supplemented with 10% (v/v) heat-inactivated fetal calf serum. All cultured cells were maintained at 37ºC in 5% CO2-95% air.
Mass spectrometry for analysis of Drp1 phosphorylation
Tryptic digestion of GST-tagged Drp1 (GST-Drp1 alone, combination of GST-Drp1 GST-PKC in the presence or absence of PKC activators) was performed as previously reported (McCormack et al., 1997) with the additional use of a MS suitable surfactant (Protease Max, Promega, WI.) and cysteine alkylation using acrylamide to avoid false positive identification, recently reported (Nielsen et al., 2008) . Each tryptic digest was run in duplicate for phosphopeptide determination. Nano reversed-phase HPLC was done using an Eksigent 2D nanoLC (Eksigent, Dublin, CA) with buffer A (0.1 % formic acid in water) and buffer B (0.1 % formic acid in acetonitrile). A self-packed fused silica column with Duragel C18 (Peeke, Redwood City, CA) matrix was used. For increased sequence coverage, two varying linear gradient nano-HPLC runs from 5 % B to 40 % B over 60 and 80 minutes respectively at a flow rate of 450 nL/minute were used. The nano-HPLC was interfaced with an Advion Nanomate (Ithaca, NY) for nano-ESI for the mass spectrometer. The mass spectrometer was a LCQ Deca XP Plus (Thermo Scientific, San Jose, CA) which was set in data-dependent acquisition mode to perform MS/MS on the top three (3) most intense ions with a dynamic exclusion setting of two (2). The .RAW files were searched against the Human IPI database using the Sequest algorithm and a Sorcerer processor (Sage-N, San Jose, CA). The allowed variable modifications were: oxidation on methionine and phosphorylation on serine, threonine and tyrosine. All peptides with a Sequest XCorr less than 2.45 were disregarded. The suggested phosphorylated peptides were manually validated for unambiguous assignment.
In vitro Drp1 phosphorylation assay
Proteins of Drp1 wild type (Drp1 WT ) and Drp1 mutant (Drp1 Ser579A ) were expressed in reticulocyte lysates using the TNT Coupled Reticulocyte Lysate System (Cell free protein expression), per the manufacturers instruction (Promega, USA). Ct = no DNA was added, representing Drp1 that is present in reticulocyte. Triton X-100 (0.1%) was added to reticulocyte after translation. Drp1 was then immunoprecipitated from reticulocyte lysate as follow: the translated proteins were incubated with anti-Drp1 antibody for 3 h at 4C, followed by incubation with protein A/G agarose beads (Santa Cruz Biotechnology, USA) for 1 h at 4C. A kinase assay (as mentioned in the paper) was performed on the immunoprecipitates in the presence of the PKC activators, phosphatidylserine (PS, 60 µg/ml) and sn-1,2 dioleoylglycerol (DG, 2 µg/ml) (PL). [No PKC was added to ct tube, representing the basal level of endogeneous phosphorylated Drp1]. The samples were loaded onto a 10% PAGE-SDS polyacrylamide gel, and the levels of phosphorylated Drp1 protein were determined by probing with Drp1 phospho Ser579 (616) antibody. Drp1 was used as loading control.
Supplemental Figure legends
Suppl. Fig. 1 . Hypertension brain injury does not change the total levels of PKC and Drp1 in the rat brain. Total lysates of rat brains in the indicated groups were analyzed by western blot for PKC and Drp1. GAPDH was used as an internal loading control. Shown are representative data of two independent experiments. Suppl. Fig. 2 . Glia cells are insensitive to hypertension-induced mitochondrial fission. Mitochondrial fragmentation was not induced by Ang II treatment in glial cells. Human astrocytoma CCF1 cells were treated with Ang II (1 M) for 6 hours and stained with Mitotracker (100 nM) for 30 min at 37C. Left panel: The mitochondrial morphology was observed by microscopy (scale bar is 0.5 m). Shown are representative data from two independent experiments. Right panel: The percentage of glial cells with fragmented mitochondria relative to the total number of cells is presented as mean  S.E. of two independent experiments. At least 100 cells per group were counted. Suppl. Fig. 3 . V1-1 has no effect on the interaction between PKC and Drp1 under normal conditions. Cultured SH-SY5Y cells were treated with V1-1 (1 M) under normal condition. The total lysates of the cells were collected. 200 g of mitochondrial fractions were subjected to immunoprecipitation (IP) with anti-Drp1 antibody and the immunoprecipitates were analyzed by immunoblotting (IB) with the indicated antibodies. The input is 10 g protein. Fig. 4 . Identification of phosphorylation site of Drp1 by PKC using mass spectrometry. GST-tagged Drp1 was incubated with or without GST-PKC in the presence or absence of PKC activators. The sequence of Drp1 was analyzed by mass spectroscopy. The near complete y-ionseries of phosphorylated peptide S570-K582 (in human Drp1 isoform 3) pinpoints the phosphorylation on S579. This phosphorylated peptide at the confidence interval >95% was only found in the group containing the combination of GST-Drp1 and GST-PKC in the presence of PKC activators. Suppl. Fig. 5 . CDK1 inhibitor inhibits Histone H3 phosphorylation. The cultured SH-SY5Y cells were treated with Calyculin A (Santa Cruz Biotechnology, to activate CDK1) followed by addition of R03306 (9 M, a gift from Dr. James Ferrell's lab), a CDK1 inhibitor. Whole cell lysates were analyzed by western blot analysis. GADPH was used as a loading control.
Suppl.
Suppl. Fig. 6 . In vitro Drp1 phosphorylation. Drp1 wild type (Drp1 WT ) and Drp1 mutant (Drp1 Ser579A ) proteins were expressed in reticulocyte lysate. Endogeneous and the translated Drp1 were immunoprecipitated with anti-Drp1 antibody. A kinase assay was performed on the immunoprecipitates in the presence of the PKC activators, phosphatidylserine (PS, 60 µg/ml) and
